<DOC>
	<DOC>NCT00077584</DOC>
	<brief_summary>In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of the present trial (RAPIDS-2) is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24-week treatment period.</brief_summary>
	<brief_title>Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Scleroderma, Systemic</mesh_term>
	<mesh_term>Scleroderma, Diffuse</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Main Systemic Sclerosis (SSc), diffuse or limited. SSc patients with at least one digital ulcer at baseline qualifying as a cardinal ulcer. Main Digital ulcers due to conditions other than SSc. Severe pulmonary arterial hypertension (PAH) (Who class III and IV). Malabsorption or any severe organ failure (e.g., lung, kidney, liver) or any lifethreatening condition. Treatment with parenteral prostanoids (prostaglandin E, epoprostenol, or prostacyclin analogs) during the past 3 months prior to randomization. Treatment with inhaled or oral prostanoids one month prior to randomization. Previous treatment with bosentan.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Scleroderma</keyword>
	<keyword>Finger Ulcers</keyword>
	<keyword>Digital Ulcers</keyword>
	<keyword>Systemic Sclerosis</keyword>
</DOC>